InflaRx (IFRX) Retained Earnings (2016 - 2026)
InflaRx's (IFRX) quarterly Retained Earnings came in at -$458.0 million in Q2 2026, down 14.01% year-over-year from -$532.7 million in Q2 2025, and down 2.04% quarter-over-quarter from -$448.9 million in Q1 2026.
Analysis
InflaRx (IFRX) Retained Earnings (2016 - 2026) Analysis & Trends
InflaRx has disclosed Retained Earnings across 11 years of filings, most recently posting -$458.0 million for Q2 2026.
- In Q2 2026, Retained Earnings fell 14.01% year-over-year to -$458.0 million; the TTM figure through Jun 2026 stood at -$458.0 million (down 14.01% YoY), while the FY2025 annual figure was -$426.9 million, down 20.25% from the prior year.
- Retained Earnings came in at -$458.0 million for Q2 2026 at InflaRx, down from -$448.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$237.4 million in Q3 2022 to a low of -$458.0 million in Q2 2026.
- Average Retained Earnings over 5 years is -$336.1 million, with a median of -$327.4 million recorded in 2024.
- Year-over-year, Retained Earnings grew 0.01% in 2022 and dropped 25.33% in 2026.
- Over 5 years, Retained Earnings stood at -$248.4 million in 2022, then fell by 23.94% to -$307.9 million in 2023, then retreated by 15.31% to -$355.0 million in 2024, then declined by 23.9% to -$439.8 million in 2025, then slipped by 4.15% to -$458.0 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$458.0 million in Q2 2026, -$448.9 million in Q1 2026, and -$439.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | -458.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -458.05 Mn |
| Mar 31, 2026 | -448.89 Mn |
| Dec 31, 2025 | -439.81 Mn |
| Sep 30, 2025 | -429.26 Mn |
| Jun 30, 2025 | -401.76 Mn |
| Mar 31, 2025 | -358.17 Mn |
| Dec 31, 2024 | -354.98 Mn |
| Sep 30, 2024 | -359.21 Mn |
| Jun 30, 2024 | -333.44 Mn |
| Mar 31, 2024 | -321.33 Mn |
| Dec 31, 2023 | -307.86 Mn |
| Sep 30, 2023 | -294.13 Mn |
| Jun 30, 2023 | -286.11 Mn |
| Mar 31, 2023 | -273.21 Mn |
| Dec 31, 2022 | -248.39 Mn |
| Sep 30, 2022 | -237.38 Mn |
| Jun 30, 2022 | -242.77 Mn |
| Mar 31, 2022 | -255.87 Mn |
| Dec 31, 2021 | -244.78 Mn |
| Sep 30, 2021 | -237.40 Mn |